India Drug Makers Eye 10% Of Production Costs On Counterfeit Prevention
This article was originally published in PharmAsia News
Major Indian drug makers, including Elder Pharmaceuticals, Glenmark Pharmaceuticals, Lupin, Ranbaxy Laboratories and Unichem Laboratories spend as much as 10% of their generic production costs on preventing counterfeits.
You may also be interested in...
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.